February 12, 2009

AVEO Pharmaceuticals to Present at Massachusetts Biotechnology Council

Download PDF

CAMBRIDGE, Mass., February 12, 2009 – AVEO Pharmaceuticals, Inc. today announced that M. Isabel Chiu, Ph.D., vice president, translational research, will lead a session for the Mass Biotechnology Council’s (MBC) Drug Discovery Committee on Thursday, February 19, 2009 at 8:00 a.m. EST in the MBC offices, in Cambridge, Mass.

Dr. Chiu’s presentation, “AVEO’s Vision: from Platform to Patients,” will focus on AVEO’s unique Human Response Platform (HRP™). The innovative HRP™ is based on the company’s proprietary genetically defined mouse models of human cancer and provides a unique preclinical setting in which to identify genetic signatures of responsive versus non-responsive tumor populations. Once identified, such signatures can then be applied in clinical development to formulate and test hypotheses and to enrich trials for patient populations likely to be responsive to a given therapy.

“I look forward to sharing AVEO’s vision and explaining our unique technology to the MBC,” stated Dr. Chiu. “By utilizing our proprietary in vivo mouse models, we believe we are better able to predict the clinical success of drug candidates in development and ultimately match the right drugs to responsive patient populations.”

For more details about this event, please visit the MBC web site at http://www.massbio.org/membership/calendar/348-aveo_pharmaceuticals.

About AVEO

AVEO is a late-stage biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. AVEO’s proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals and Schering-Plough. The company’s lead product, AV-951, a potential best-in-class triple VEGF receptor inhibitor, is in a Phase 2 clinical trial in patients with metastatic renal cell cancer and is expected to enter Phase 3 development in 2009. Through a combination of internal drug discovery and selective in-licensing of targeted therapeutics, AVEO is building a diversified product pipeline and moving toward its vision of becoming a fully integrated biopharmaceutical company. For more information, please visit the company’s website at www.aveopharma.com.